PharMerica Acquires Luker Pharmacy Management

Transaction Expands Company’s Hospital Pharmacy Management Business

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), a diversified national provider of institutional and specialty pharmacy services, announced today that it has completed the acquisition of Luker Pharmacy Management (“Luker”). Terms of the transaction were not disclosed.

Luker provides comprehensive pharmacy management services to hospitals and other healthcare facilities, primarily in Texas.

Greg Weishar, PharMerica Corporation’s Chief Executive Officer stated, “The acquisition of Luker Pharmacy Management further expands our hospital pharmacy management business and capabilities.

Mr. Weishar continued, “We look forward to working with the Luker management team and the Company’s outstanding client base to continue providing excellent service to customers and growing the business.”

About PharMerica

PharMerica Corporation is a leading provider of pharmacy services. PharMerica serves the long-term care, hospital pharmacy management services, specialty home infusion and oncology pharmacy markets. PharMerica operates 94 institutional pharmacies, 15 specialty home infusion pharmacies and 5 specialty oncology pharmacies in 45 states. PharMerica’s customers are institutional healthcare providers, such as skilled nursing facilities, assisted living facilities, hospitals, individuals receiving in-home care and patients with cancer.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151105006603/en/

PharMerica Corporation
David W. Froesel, Jr., 502-627-7950
Executive Vice President,
Chief Financial Officer and Treasurer

Source: PharMerica Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• GameStop drops Cohen’s $35B pay plan to focus on eBay acquisition
• Xinjiang Today: Seeing 'a Huge Place' through experienced eyes
• Sportradar Securities Fraud Class Action Result of Compliance Misrepresentations and 22% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC